Filter Results:
(924)
Show Results For
- All HBS Web
(1,278)
- People (5)
- News (171)
- Research (924)
- Events (6)
- Multimedia (12)
- Faculty Publications (756)
Show Results For
- All HBS Web
(1,278)
- People (5)
- News (171)
- Research (924)
- Events (6)
- Multimedia (12)
- Faculty Publications (756)
Sort by
- January 2016 (Revised January 2019)
- Supplement
The Allergan Board Under Fire (B)
By: Lynn S. Paine, Suraj Srinivasan, John C. Coates and David Lane
In 2014, the Allergan Inc. board of directors received a surprise takeover offer from Valeant Pharmaceuticals in alliance with hedge fund activist Bill Ackman's Pershing Square Capital Management. In the unprecedented arrangement between an acquirer and a hedge fund... View Details
Keywords: Allergan, Inc.; Valeant; Ackman; Pershing Square; Tender Offer; Activist Investors; Business Models; R＆D; Board Of Directors; Securities Litigation; Acquisition Strategy; Takeover Defenses; Hedge Funds; Shareholder Rights; Proxy Contest; Shareholder Special Meetings; Legal Issues In Contested Takeovers; Corporate Governance; Investment Activism; Business and Stakeholder Relations; Business Model; Business and Shareholder Relations; Valuation; Pharmaceutical Industry
Paine, Lynn S., Suraj Srinivasan, John C. Coates, and David Lane. "The Allergan Board Under Fire (B)." Harvard Business School Supplement 316-029, January 2016. (Revised January 2019.)
- Research Summary
Research Interests
Research interests are focused on issues of innovation and productivity as they relate to improved outcomes in biotechnology and pharmaceutical R and D. These span topics from decision-making, organizational structure and communication, to the development of novel... View Details
- May 2014
- Article
Right Up the Middle: How Israeli Firms Go Global
By: Jonathan Friedrich, Amit Noam and Elie Ofek
The article considers international business enterprises based in Israel and how they successfully expanded from their origins as small businesses. A common technique of those companies in which they focused on market entry in other countries whose markets were too... View Details
Friedrich, Jonathan, Amit Noam, and Elie Ofek. "Right Up the Middle: How Israeli Firms Go Global." Harvard Business Review 92, no. 5 (May 2014): 113–117.
- December 2008 (Revised April 2010)
- Case
Proteus Biomedical: Making Pigs Fly
By: Richard G. Hamermesh, Lauren Barley and Ginger Graham
Proteus is a healthcare start-up that has developed technology to embed electronics for computing and sensing in existing medical devices and drugs. The technology could potentially change the basis of competition in the pharmaceutical industry. The company is... View Details
Keywords: Business Startups; Entrepreneurship; Technological Innovation; Rights; Negotiation Deal; Business Strategy; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry
Hamermesh, Richard G., Lauren Barley, and Ginger Graham. "Proteus Biomedical: Making Pigs Fly." Harvard Business School Case 809-051, December 2008. (Revised April 2010.)
- October 2023 (Revised June 2024)
- Case
Catalent: Catalyzing the Next Era of Growth
By: Satish Tadikonda, William Marks and Kevin Emancipator
Catalent's newly appointed CEO, Alessandro Maselli, experienced the highs of the pharmaceutical contract development manufacturing (CDMO) space during COVID-19 while helping Moderna and others bring vaccines to market quickly and safely. After rushing to add capacity... View Details
Keywords: Leadership; Business or Company Management; Organizational Change and Adaptation; Pharmaceutical Industry
Tadikonda, Satish, William Marks, and Kevin Emancipator. "Catalent: Catalyzing the Next Era of Growth." Harvard Business School Case 824-016, October 2023. (Revised June 2024.)
- November 2006
- Case
Selling Biovail Short
By: Malcolm P. Baker, Chris Lombardi and Aldo Sesia
Hedge fund SAC Capital and analysts from Gradient Analytics and Banc of America face charges of stock price manipulation from Biovail, a Canadian pharmaceutical company. Gradient and BofA produced negative reports on Biovail's earnings quality. At the same time, SAC... View Details
Keywords: Stock Shares; Investment Banking; Asset Pricing; Financial Strategy; Crime and Corruption; Pharmaceutical Industry; Pharmaceutical Industry; Canada
Baker, Malcolm P., Chris Lombardi, and Aldo Sesia. "Selling Biovail Short." Harvard Business School Case 207-071, November 2006.
- January 2001
- Case
Merck Global Health Initiatives (B): Botswana
By: James E. Austin, Diana Barrett and James Weber
The case series focuses on Merck's drug donation program and then raises new issues facing management about what to do about HIV/AIDS in Africa given the company's development of a new therapy. Describes collaboration among many parties including the Gates Foundation,... View Details
Keywords: Health Disorders; Health Care and Treatment; Private Sector; Public Sector; Alliances; Problems and Challenges; Africa; Botswana
Austin, James E., Diana Barrett, and James Weber. "Merck Global Health Initiatives (B): Botswana." Harvard Business School Case 301-089, January 2001.
- February 1996
- Case
Chadwick, Inc.: The Balanced Scorecard (Abridged)
By: Robert S. Kaplan
The pharmaceutical division of a diversified company has been asked to develop a Balanced Scorecard. Research and development projects take about ten years to bring a new product to the marketplace and the division depends on good relations and active feedback from its... View Details
Keywords: Balanced Scorecard; Research and Development; Product Launch; Commercialization; Consumer Behavior; Customer Focus and Relationships; Performance Evaluation; Pharmaceutical Industry
Kaplan, Robert S. "Chadwick, Inc.: The Balanced Scorecard (Abridged)." Harvard Business School Case 196-124, February 1996.
- February 1997
- Case
Archer Daniels Midland: Direction and Strategy
By: Ray A. Goldberg and Thomas N. Urban Jr
Sets out the strategy and competitive competencies of one of the leading grain trade and processing companies in the world. An overview of the company's innovations in corn and oilseed by-products is provided. The strategy of the firm is to add by-products to corn,... View Details
Keywords: Innovation and Invention; Strategic Planning; Business Strategy; Value Creation; Pharmaceutical Industry; Pharmaceutical Industry
Goldberg, Ray A., and Thomas N. Urban Jr. "Archer Daniels Midland: Direction and Strategy." Harvard Business School Case 597-039, February 1997.
- August 2013
- Teaching Plan
Remicade-Simponi
By: Guhan Subramanian and Charlotte Krontiris
This exercise models a negotiation between two pharmaceutical companies—Johnson & Johnson and Merck—concerning the international distribution rights for Remicade, a blockbuster anti-arthritis drug. At odds over the original distribution contract, the two companies... View Details
Keywords: Johnson ＆ Johnson; Merck; Negotiation; Negotiation Participants; Negotiation Deal; Pharmaceutical Industry
Subramanian, Guhan, and Charlotte Krontiris. "Remicade-Simponi." Harvard Business School Teaching Plan 914-006, August 2013.
- August 2003 (Revised August 2006)
- Case
New Sector Alliance (A): An Entry into Health Care?
By: Regina E. Herzlinger, Stacy Smollin Schwartz and Jeffrey Cronin
Describes the structure of the U.S. health care system and presents a study of a nonprofit consulting firm that hopes to enter the health care system. Includes descriptions of hospitals, doctors, insurers, medical technology providers, medical devices, pharmaceuticals,... View Details
Keywords: Health; Health Care and Treatment; Health Disorders; Nonprofit Organizations; Health Industry; United States
Herzlinger, Regina E., Stacy Smollin Schwartz, and Jeffrey Cronin. "New Sector Alliance (A): An Entry into Health Care?" Harvard Business School Case 304-004, August 2003. (Revised August 2006.)
- August 2013 (Revised October 2013)
- Case
MedImmune Ventures
By: Richard G. Hamermesh and David Lane
Ron Laufer is the new Senior Managing Director of MedImmune Ventures, the corporate venture capital arm of AstraZeneca, a leading pharmaceuticals firm. Laufer has to decide whether to pursue a high-potential, but very risky, early-stage investment. The decision Laufer... View Details
Keywords: MedImmune; MedImmune Ventures; AstraZeneca; NeuProtect; Corporate Venturing; Biotechnology; Venture Investing; Venture Capital; Health Care and Treatment; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; United States; Australia; Europe; London
Hamermesh, Richard G., and David Lane. "MedImmune Ventures." Harvard Business School Case 814-023, August 2013. (Revised October 2013.)
- January 1994 (Revised July 1998)
- Case
Repligen Corporation: January 1992
By: Josh Lerner and David Kane
Sandford Smith, CEO of Repligen, faces the breakdown of negotiations about a proposed joint venture with a large pharmaceutical firm. He must decide whether to proceed using his firm's internal resources or whether to seek to revise the proposed collaboration. If the... View Details
Lerner, Josh, and David Kane. "Repligen Corporation: January 1992." Harvard Business School Case 294-082, January 1994. (Revised July 1998.)
- August 2005 (Revised December 2006)
- Case
Procter & Gamble: Electronic Data Capture and Clinical Trial Management
By: Robert S. Huckman and Mark J. Cotteleer
Considers whether the management of Procter & Gamble (P&G) Pharmaceuticals should adopt Web-based electronic data capture (EDC) as the default standard for the management of its clinical drug trials. Provides a detailed description of the existing paper-based process... View Details
Keywords: Health Testing and Trials; Internet and the Web; Information Technology; Adoption; Business Processes; Industry Structures; Technological Innovation; Service Operations; Pharmaceutical Industry; United States
Huckman, Robert S., and Mark J. Cotteleer. "Procter & Gamble: Electronic Data Capture and Clinical Trial Management." Harvard Business School Case 606-033, August 2005. (Revised December 2006.)
- April 2009 (Revised November 2012)
- Case
Sermo, Inc.
By: Thomas R. Eisenmann and Lars Peter Christian Nielsen
Sermo operates the leading online professional network for physicians in the United States. Doctors use Sermo free of charge to post surveys regarding diagnostic and treatment concerns and to discuss these concerns, as well as challenges with managing their practices.... View Details
Keywords: Entrepreneurship; Health Care and Treatment; Knowledge Sharing; Two-Sided Platforms; Conflict and Resolution; Social and Collaborative Networks; United States
Eisenmann, Thomas R., and Lars Peter Christian Nielsen. "Sermo, Inc." Harvard Business School Case 809-142, April 2009. (Revised November 2012.)
- Research Summary
AIDS in Africa: Life, Death and Property Rights
By: Debora L. Spar
In the final years of the twentieth century, the world was hit by a plague of epidemic proportions--the plague of AIDS, a life-threatening disease that remained stubbornly immune to any cure or vaccine. In the developed nations of the West, AIDS was slowly brought... View Details
- January 2001 (Revised May 2003)
- Case
Novartis Pharma: The Business Unit Model
By: Srikant M. Datar, Carin-Isabel Knoop and Cate Reavis
In June 2000, Novartis reorganized its pharmaceutical business to form global business units in oncology, transplantation, ophthalmology, and mature products. The remaining primary care products continued to be managed within global functions (e.g., R&D and marketing).... View Details
Keywords: Restructuring; Recruitment; Product Marketing; Organizational Structure; Problems and Challenges; Pharmaceutical Industry; Pharmaceutical Industry
Datar, Srikant M., Carin-Isabel Knoop, and Cate Reavis. "Novartis Pharma: The Business Unit Model." Harvard Business School Case 101-030, January 2001. (Revised May 2003.)
- March 2008 (Revised March 2022)
- Case
Cadbury Schweppes: Capturing Confectionery (A)
By: David Collis, Toby Stuart and Troy Smith
In late 2002, global confectionery and beverage maker Cadbury Schweppes needed to decide whether or not to make an acquisition bid for Adams, an underperforming gum company which had been put up for sale by pharmaceutical giant Pfizer. Examining the decision from a... View Details
Keywords: Business History; Strategy; Decision Choices and Conditions; Mergers and Acquisitions; Food and Beverage Industry
Collis, David, Toby Stuart, and Troy Smith. "Cadbury Schweppes: Capturing Confectionery (A)." Harvard Business School Case 708-453, March 2008. (Revised March 2022.)
- 2012
- Chapter
Evidence from the Firm: A New Approach to Understanding Corruption
By: Shawn A. Cole and Anh Tran
Due to its clandestine nature, most of what we understand about corruption comes from survey evidence and self-reported perceptions of corruption: this limits both the range of questions that can be asked and the precision of answers that can be provided. This chapter... View Details
- March 1994 (Revised April 1994)
- Case
Eli Lilly and Co.: The Flexible Facility Decision--1993
By: Gary P. Pisano
In 1993, Eli Lilly is preparing to build manufacturing capacity for three new pharmaceutical products that it expects to launch in 1996. Management wrestles with a decision of whether to add specialized manufacturing capacity or flexible capacity. This question touches... View Details
Keywords: Debates; Cost vs Benefits; Decisions; Investment; Goals and Objectives; Product Launch; Production; Corporate Strategy; Pharmaceutical Industry
Pisano, Gary P. "Eli Lilly and Co.: The Flexible Facility Decision--1993." Harvard Business School Case 694-074, March 1994. (Revised April 1994.)